The Benefits of Tight Glycemic Control in Type 2 Diabetes Mellitus

Haffner, 1998, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction, N Engl J Med, 339, 229, 10.1056/NEJM199807233390404 2006, Standards of medical care in diabetes-2006, Diabetes Care, 29, S4, 10.2337/diacare.29.s1.06.s4 2003, Economic costs of diabetes in the U.S. in 2002, Diabetes' Care, 26, 917, 10.2337/diacare.26.3.917 Knopp, 2006, Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of coronary heart disease Endpoints in Non-insulin-dependent diabetes mellitus (ASPEN), Diabetes Care, 29, 1478, 10.2337/dc05-2415 Selvin, 2005, Glycemic control and coronary heart disease risk in persons with and without diabetes: The Atherosclerosis Risk in Communities Study, Arch Intern Med, 165, 1910, 10.1001/archinte.165.16.1910 Laakso, 1996, Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The Finnish studies, Ann Intern Med, 124, 127, 10.7326/0003-4819-124-1_Part_2-199601011-00009 Lehto, 1997, Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM, Diabetes, 46, 1354, 10.2337/diabetes.46.8.1354 1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 Mudaliar, 2004, Intense management of diabetes mellitus: Role of glucose control and antiplatelet agents, J Clin Pharmacol, 44, 414, 10.1177/0091270004263045 Burchfiel, 1997, Cardiovascular risk factors and hyalinization of renal arterioles at autopsy. The Honolulu Heart Program, Arterioscler Thromb Vasc Biol, 17, 760, 10.1161/01.ATV.17.4.760 Chiasson, 2003, Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOPNIDDM trial, JAMA, 290, 486, 10.1001/jama.290.4.486 Delorme, 2005, Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus, Curr Opin Pharmacol, 5, 184, 10.1016/j.coph.2004.11.005 1998, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8 Stratton, 2000, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study, BMJ, 321, 405, 10.1136/bmj.321.7258.405 Schellhase, 2005, Glycemic control and the risk of multiple microvascular diabetic complications, Fam Med, 37, 139 Nathan, 2006, Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 29, 1963, 10.2337/dc06-9912 Lebovitz, 2006, ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: Consensus conference recommendations, Endocr Pract, 12, 6, 10.4158/EP.12.S1.6 LeRoith, 2005, Monitoring glycemic control: The cornerstone of diabetes care, Clin Ther, 27, 1489, 10.1016/j.clinthera.2005.10.010 Dandona, 2002, A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis, Am J Cardiol., 90, 27G, 10.1016/S0002-9149(02)02556-0 Ratner, 2005, Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program, Diabetes Care, 28, 888, 10.2337/diacare.28.4.888 Donner, 2006, Tight control of hyperglycemia in type 2 diabetes mellitus, Insulin, 1, 166, 10.1016/S1557-0843(06)80037-0 Rayfield, 2006, Chapter 2: Pathophysiology and clinical management of diabetes and prediabetes, 15 Giannarelli, 2003, Reducing insulin resistance with metformin: The evidence today, Diabetes Metab, 29, 6S28, 10.1016/S1262-3636(03)72785-2 Avenell, 2004, Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement, Health Technology Assessment, 8, 36, 10.3310/hta8210 Van de Laar, 2005, Alpha-glucosidase inhibitors for type 2 diabetes mellitus Wagner, 2006, Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes, Diabetes Care, 29, 1471, 10.2337/dc05-2513 Sharma, 2007, Peroxisome proliferator-activated receptor gamma and adipose tissue—understanding obesity-related changes in regulation of lipid and glucose metabolism, J Clin Endocrinol Metab, 92, 386, 10.1210/jc.2006-1268 Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial, Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9 Murata, 2004, Hypoglycemia in type 2 diabetes: A critical review, Biomed Pharmacother, 58, 551, 10.1016/j.biopha.2004.09.001 Scheen, 2006, Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study, Lancet, 368, 1660, 10.1016/S0140-6736(06)69571-8 Wing, 1987, Type II diabetic subjects lose less weight than their overweight non-diabetic spouses, Diabetes Care, 10, 563, 10.2337/diacare.10.5.563 Guare, 1995, Comparison of obese NIDDM and nondiabetic women: Short- and long-term weight loss, Obes Res, 3, 329, 10.1002/j.1550-8528.1995.tb00158.x Drucker, 2006, The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, Lancet, 368, 1696, 10.1016/S0140-6736(06)69705-5 Byetta® (exenatide injection) Prescribing Information. Amylin Pharmaceuticals, Inc; San Diego, Calif. Literature revised February 2007. Available at:. Accessed February 12, 2007. Januvia™ (sitagliptin tablets) Prescribing Information. Merck & Co, Inc; Whitehouse Station, NJ. 2006. Available at:. Accessed February 12, 2007. Tangalos, 2006, Complex cardiometabolic risk factors: Impact, assessment, and emerging therapies, J Am Med Dir Assoc, 7, 1, 10.1016/j.jamda.2006.06.003 Kyrou, 2006, The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome, Ann NY Acad Sci, 1083, 270, 10.1196/annals.1367.024 Engeli, 2005, Activation of the peripheral endocannabinoid system in human obesity, Diabetes, 54, 2838, 10.2337/diabetes.54.10.2838 Van Gaal, 2005, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-Year experience from the RIO-Europe study, Lancet, 365, 1389, 10.1016/S0140-6736(05)66374-X Pi-Sunyer, 2006, Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial, JAMA, 295, 761, 10.1001/jama.295.7.761 Després JR Golay, 2005, Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia, N Engl J Med, 353, 2121, 10.1056/NEJMoa044537